

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:  
Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 29<sup>th</sup> day of November 2006.

(Signature of person mailing)

Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Paul S. Changelian

Serial No.: 10/720,600

Filed: November 24, 2003

Title: METHOD OF TREATMENT OF  
TRANSPLANT REJECTION

Group Art Unit: 1624

Examiner: V. Balasubramanian

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER TO OBVIATE  
A DOUBLE PATENTING REJECTION**

Sir:

Petitioner, Pfizer Inc, hereby states that it is the assignee of the entire right, title and interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§154 to 156 and 173, of prior United States Patent Nos. 6,627,754; 6,956,041; and 7,091,208, as may be shortened by any terminal disclaimer. Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patents are commonly

owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, Petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patents, as may be shortened by any terminal disclaimer, in the event that the prior patents later: expire for failure to pay a maintenance fee; are held unenforceable; are found invalid by a court of competent jurisdiction; are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321; has all claims canceled by a reexamination certificate; are reissued; or are in any manner terminated prior to the expiration of its full statutory term as may be shortened by any terminal disclaimer.


The undersigned (whose title is supplied below) is empowered to act on behalf of Petitioner. The present application is assigned by virtue of an assignment from the named inventor to Pfizer Inc, which was recorded with the USPTO on December 30, 2002, a copy of which can be found at the Reel/Frame Number 013631/0131.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The Commissioner is hereby authorized by this paper to charge the required fee under 37 C.F.R. §§ 1.321(b)(4) and 1.20(d) to Deposit Account 16-1445. The Commissioner is hereby authorized by this paper to charge any additional fees that may be required or credit any overpayment to Deposit Account 16-1445.

Respectfully submitted,

Date: November 29, 2006

  
\_\_\_\_\_  
Christopher J. Verni  
Attorney for Applicant  
Reg. No. 48,322

**Customer No. 28523**  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 686-2032